Attovia Therapeutics, a CA-based company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer, raised $60M in Series A funding.
The round was led by Frazier and joined by venBio and Illumina Ventures. Jamie Topper, M.D. Ph.D., managing partner at Frazier Life Sciences and Aaron Royston, M.D., M.B.A., managing partner at venBio, will join the Attovia’s Board of Directors.
The company plans to use the proceeds to achieve clinical proof-of-concept on its lead program in immune-mediated disease, nominate additional development candidates across its core areas of focus in immunology and oncology, as well as continue to advance the core Attobody technology platform.
Launched by Alamar Biosciences and Frazier Life Sciences, Attovia is focused on creating a pipeline of biotherapeutics in immune-mediated disease and oncology. The company leverages Attobody™, Alamar Biosciences’ novel biparatopic nanobody platform, to generate small format binders with low picomolar affinity, enhanced specificity, accelerated internalization and fast tissue penetration. Its lead program is an Attobody to treat immune disease. Attovia is currently progressing multiple programs and plans to initiate additional discovery projects.
The company will receive an exclusive world-wide license to the Attobody platform and associated intellectual property and pipeline assets in the therapeutic field in exchange for equity and potential milestones and royalties.
Tao Fu, M.S., M.B.A., co-founder of Attovia and Venture Partner at Frazier Life Sciences, will serve as Attovia’s chief executive officer and join the Board. Mr. Fu is a seasoned industry leader with over 25 years of executive experience in the pharmaceutical and biotech industries, including leadership roles at Zai Lab, Portola Pharmaceuticals, Bristol-Myers Squibb, and Johnson & Johnson. The leadership team is fully rounded out by Petter Veiby, Ph.D., chief scientific officer; Hangjun Zhan, Ph.D., chief technology officer; and Zaneta Odrowaz, Ph.D., chief business officer.
FinSMEs
21/06/2023